Pan-Cancer Analysis and Validation of Opioid-Related Receptors Reveals the Immunotherapeutic Value of Toll-Like Receptor 4

References

• Cronin-Fenton D. Opioids and breast cancer recurrence. Curr Opin Support Palliat Care. 2019;13(2):88–93. doi:10.1097/SPC.0000000000000426
   PubMed Web of Science ®Google Scholar
• Szczepaniak A, Fichna J, Zielińska M. Opioids in Cancer Development, Progression and Metastasis: focus on Colorectal Cancer. Curr Treat Options Oncol. 2020;21(1):6. doi:10.1007/s11864-019-0699-1
   PubMed Web of Science ®Google Scholar
• Vaseghi G, Ghasemi A, Laher I, et al. Morphine upregulates Toll-like receptor 4 expression and promotes melanomas in mice. Immunopharmacol Immunotoxicol. 2022;1–8.
   Web of Science ®Google Scholar
• Oh TK, Jeon JH, Lee JM, et al. Association of high-dose postoperative opioids with recurrence risk in esophageal squamous cell carcinoma: reinterpreting ERAS protocols for long-term oncologic surgery outcomes. Dis Esophagus. 2017;30(10):1–8. doi:10.1093/dote/dox074
   PubMed Web of Science ®Google Scholar
• Kim R. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence. J Transl Med. 2018;16(1):8. doi:10.1186/s12967-018-1389-7
   PubMed Web of Science ®Google Scholar
• Kim R. Anesthetic technique and cancer recurrence in oncologic surgery: unraveling the puzzle. Cancer Metastasis Rev. 2017;36(1):159–177. doi:10.1007/s10555-016-9647-8
   PubMed Web of Science ®Google Scholar
• Tai YH, Wu HL, Chang WK, et al. Intraoperative Fentanyl Consumption Does Not Impact Cancer Recurrence or Overall Survival after Curative Colorectal Cancer Resection. Sci Rep. 2017;7:10816. doi:10.1038/s41598-017-11460-1
   PubMed Web of Science ®Google Scholar
• Du KN, Feng L, Newhouse A, et al. Effects of Intraoperative Opioid Use on Recurrence-Free and Overall Survival in Patients With Esophageal Adenocarcinoma and Squamous Cell Carcinoma. Anesth Analg. 2018;127(1):210–216. doi:10.1213/ANE.0000000000003428
   PubMed Web of Science ®Google Scholar
• Sessler DI, Pei L, Huang Y, et al. Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. Lancet. 2019;394(10211):1807–1815. doi:10.1016/S0140-6736(19)32313-X
   PubMed Web of Science ®Google Scholar
• Montagna G, Gupta HV, Hannum M, et al. Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer. Br J Anaesth. 2021;126(2):367–376. doi:10.1016/j.bja.2020.10.021
   PubMed Web of Science ®Google Scholar
• Boland JW, Pockley AG. Influence of opioids on immune function in patients with cancer pain: from bench to bedside. Br J Pharmacol. 2018;175(14):2726–2736. doi:10.1111/bph.13903
   PubMed Web of Science ®Google Scholar
• Kim R, Kawai A, Wakisaka M, et al. Current Status and Prospects of Anesthesia and Breast Cancer: does Anesthetic Technique Affect Recurrence and Survival Rates in Breast Cancer Surgery? Front Oncol. 2022;12:795864. doi:10.3389/fonc.2022.795864
   PubMed Web of Science ®Google Scholar
• Ma Y, Ren Z, Ma S, et al. Morphine enhances renal cell carcinoma aggressiveness through promotes survivin level. Ren Fail. 2017;39(1):258–264. doi:10.1080/0886022X.2016.1256322
   PubMed Web of Science ®Google Scholar
• Chen D, Chen Y, Yan Y, et al. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients. BMC Cancer. 2017;17(1):553. doi:10.1186/s12885-017-3541-9
   PubMedGoogle Scholar
• Connolly C, Madden SF, Buggy DJ, et al. Expression of anaesthetic and analgesic drug target genes in excised breast tumour tissue: association with clinical disease recurrence or metastasis. PLoS One. 2017;12:e0177105.
   PubMed Web of Science ®Google Scholar
• Ramirez MF, Gorur A, Cata JP. Opioids and cancer prognosis: a summary of the clinical evidence. Neurosci Lett. 2021;746:135661. doi:10.1016/j.neulet.2021.135661
   PubMed Web of Science ®Google Scholar
• Xie N, Matigian N, Vithanage T, et al. Effect of Perioperative Opioids on Cancer-Relevant Circulating Parameters: mu Opioid Receptor and Toll-Like Receptor 4 Activation Potential, and Proteolytic Profile. Clin Cancer Res. 2018;24(10):2319–2327. doi:10.1158/1078-0432.CCR-18-0172
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14(1):7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4(1):2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Bonneville R, Krook MA, Kautto EA, et al. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol. 2017;2017. doi:10.1200/PO.17.00073
   PubMed Web of Science ®Google Scholar
• Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929–1935. doi:10.1126/science.1132939
   PubMed Web of Science ®Google Scholar
• Subramanian A, Narayan R, Corsello SM, et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell. 2017;171(6):1437–52.e17. doi:10.1016/j.cell.2017.10.049
   PubMed Web of Science ®Google Scholar
• Guo T, Jiang L, Wang T, et al. Screening and identification of prognostic genes associated with eosinophilic features of clear cell renal cell carcinoma. Heliyon. 2023;9:e16479.
   PubMed Web of Science ®Google Scholar
• Kao TJ, Wu CC, Phan NN, et al. Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer. Aging. 2021;13:17970. doi:10.18632/aging.203345
   PubMedGoogle Scholar
• Anh ND, Thuong PH, Sim NT, et al. Maternal vascular endothelial growth factor receptor and interleukin levels in pregnant women with twin-twin transfusion syndrome. Int J Med Sci. 2021;18(14):3206–3213. doi:10.7150/ijms.61014
   PubMed Web of Science ®Google Scholar
• Belltall A, Zúñiga-Trejos S, Garrido-Cano I, et al. Solid Tumor Opioid Receptor Expression and Oncologic Outcomes: analysis of the Cancer Genome Atlas and Genotype Tissue Expression Project. Front Oncol. 2022;12:801411. doi:10.3389/fonc.2022.801411
   PubMed Web of Science ®Google Scholar
• Yang M, Miao Y-R, Xie G-Y, et al. ICBatlas: a Comprehensive Resource for Depicting Immune Checkpoint Blockade Therapy Characteristics from Transcriptome Profiles. Cancer Immunol Res. 2022;10(11):1398–1406. doi:10.1158/2326-6066.CIR-22-0249
   PubMed Web of Science ®Google Scholar
• Ye L, Li C, Jiang W, et al. Subacute toxicity evaluations of LPM3480392 in rats, a full µ-opioid receptor biased agonist. Front Pharmacol. 2023;14:1218380. doi:10.3389/fphar.2023.1218380
   PubMed Web of Science ®Google Scholar
• Wall T, Sherwin A, Ma D, et al. Influence of perioperative anaesthetic and analgesic interventions on oncological outcomes: a narrative review. Br J Anaesth. 2019;123(2):135–150. doi:10.1016/j.bja.2019.04.062
   PubMed Web of Science ®Google Scholar
• Qu N, Wang X, Meng Y, et al. Prospective oncotarget for gynecological cancer: opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis. Int Immunopharmacol. 2019;75:105723. doi:10.1016/j.intimp.2019.105723
   PubMed Web of Science ®Google Scholar
• Afsharimani B, Doornebal CW, Cabot PJ, et al. Comparison and analysis of the animal models used to study the effect of morphine on tumour growth and metastasis. Br J Pharmacol. 2015;172(2):251–259. doi:10.1111/bph.12589
   PubMed Web of Science ®Google Scholar
• Zurakowski D, Staffa SJ. Statistical power and sample size calculations for time-to-event analysis. J Thorac Cardiovasc Surg. 2022. doi:10.1016/j.jtcvs.2022.09.023
   Web of Science ®Google Scholar
• Lec PM, Lenis AT, Golla V, et al. The Role of Opioids and Their Receptors in Urological Malignancy: a Review. J Urol. 2020;204(6):1150–1159. doi:10.1097/JU.0000000000001156
   PubMed Web of Science ®Google Scholar
• Haque MR, Barlass U, Armstrong A, et al. Novel role of the Mu-opioid receptor in pancreatic cancer: potential link between opioid use and cancer progression. Mol Cell Biochem. 2022;477(5):1339–1345. doi:10.1007/s11010-022-04377-5
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang S, Jin D, et al. μ-opioid receptor agonist facilitates circulating tumor cell formation in bladder cancer via the MOR/AKT/Slug pathway: a comprehensive study including randomized controlled trial. Cancer Commun. 2023.
   Web of Science ®Google Scholar
• Brejchova J, Holan V, Svoboda P, Geyer J. Expression of Opioid Receptors in Cells of the Immune System. Int J Mol Sci. 2020;22(1):22. doi:10.3390/ijms22010022
   PubMed Web of Science ®Google Scholar
• Choi H, Hwang W. Perioperative Inflammatory Response and Cancer Recurrence in Lung Cancer Surgery: a Narrative Review. Front Surg. 2022;9:888630. doi:10.3389/fsurg.2022.888630
   PubMed Web of Science ®Google Scholar
• Cuitavi J, Lorente JD, Campos-Jurado Y, et al. Neuroimmune and Mu-Opioid Receptor Alterations in the Mesocorticolimbic System in a Sex-Dependent Inflammatory Pain-Induced Alcohol Relapse-Like Rat Model. Front Immunol. 2021;12:689453. doi:10.3389/fimmu.2021.689453
   PubMed Web of Science ®Google Scholar
• Wen S, Jiang Y, Liang S, et al. Opioids Regulate the Immune System: focusing on Macrophages and Their Organelles. Front Pharmacol. 2021;12:814241. doi:10.3389/fphar.2021.814241
   PubMed Web of Science ®Google Scholar
• Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566–576. doi:10.1038/s41591-020-0805-8
   PubMed Web of Science ®Google Scholar
• Zheng T, Qiu J, Li C, et al. Long noncoding RNA LINC00673 promotes the proliferation and metastasis of epithelial ovarian cancer by associating with opioid growth factor receptor. Onco Targets Ther. 2019;12:6145–6156. doi:10.2147/OTT.S209784
   PubMed Web of Science ®Google Scholar
• Huang H, Liu B, Qu N, et al. Research progress of opioid growth factor in immune-related diseases and cancer diseases. Int Immunopharmacol. 2021;99:107713. doi:10.1016/j.intimp.2021.107713
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang Y, Shan F. Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy. Int Immunopharmacol. 2019;75:105785. doi:10.1016/j.intimp.2019.105785
   PubMed Web of Science ®Google Scholar
• Anuraga G, Wang WJ, Phan NN, et al. Potential Prognostic Biomarkers of NIMA (Never in Mitosis, Gene A)-Related Kinase (NEK) Family Members in Breast Cancer. J Pers Med. 2021;12(1):11. doi:10.3390/jpm12010011
   PubMedGoogle Scholar
• Xing C, Wang Z, Zhu Y, et al. Integrate analysis of the promote function of Cell division cycle-associated protein family to pancreatic adenocarcinoma. Int J Med Sci. 2021;18(3):672–684. doi:10.7150/ijms.53243
   PubMed Web of Science ®Google Scholar
• Modhukur V, Iljasenko T, Metsalu T, et al. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2018;10(3):277–288. doi:10.2217/epi-2017-0118
   PubMed Web of Science ®Google Scholar
• Shetab Boushehri MA, Lamprecht A. TLR4-Based Immunotherapeutics in Cancer: a Review of the Achievements and Shortcomings. Mol Pharm. 2018;15(11):4777–4800. doi:10.1021/acs.molpharmaceut.8b00691
   PubMed Web of Science ®Google Scholar
• Papadakos SP, Arvanitakis K, Stergiou IE, et al. The Role of TLR4 in the Immunotherapy of Hepatocellular Carcinoma: can We Teach an Old Dog New Tricks? Cancers. 2023;15.
   PubMedGoogle Scholar
• Eriksen E, Afanou AK, Straumfors A, et al. Bioaerosol-induced in vitro activation of toll-like receptors and inflammatory biomarker expression in waste workers. Int Arch Occup Environ Health. 2023;96(7):985–998. doi:10.1007/s00420-023-01984-7
   PubMed Web of Science ®Google Scholar
• Bošnjak B, Kth D, Förster R, et al. Imaging dendritic cell functions*. Immunol Rev. 2022;306:137–163. doi:10.1111/imr.13050
   PubMed Web of Science ®Google Scholar
• Sanchez-Ruiz M, Iorgu AM, Küster F, et al. CD8 T cell-Derived Perforin and TNF-α Are Crucial Mediators of Neuronal Destruction in Experimental Autoimmune Enteric Ganglionitis. Am J Pathol. 2021;191:1064–1076. doi:10.1016/j.ajpath.2021.02.021
   PubMed Web of Science ®Google Scholar
• Niogret J, Berger H, Rebe C, et al. Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy. J ImmunoTherapy Cancer. 2021;9:e002157. doi:10.1136/jitc-2020-002157
   PubMedGoogle Scholar
• Velasco WV, Khosravi N, Castro-Pando S, et al. Toll-like receptors 2, 4, and 9 modulate promoting effect of COPD-like airway inflammation on K-ras-driven lung cancer through activation of the MyD88/NF-ĸB pathway in the airway epithelium. Front Immunol. 2023;14:1118721. doi:10.3389/fimmu.2023.1118721
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012;1:894–907. doi:10.4161/onci.20931
   PubMed Web of Science ®Google Scholar
• Wang CY, Chiao CC, Phan NN, et al. Gene signatures and potential therapeutic targets of amino acid metabolism in estrogen receptor-positive breast cancer. Am J Cancer Res. 2020;10:95–113.
   PubMed Web of Science ®Google Scholar